Patent Expirations And Generics Will Erode Revenues Yet Spark Hope
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
26 Apr 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$145.00
18.8% undervalued intrinsic discount16 Aug
US$117.77
1Y
3.1%7D
6.3%